

# Synthesis of pyrrolo[3,4-*c*]quinolines by 1,5-electrocyclisation of non-stabilised azomethine ylides

Miklós Nyerges,<sup>a,\*</sup> Áron Pintér,<sup>a</sup> Andrea Virányi,<sup>a</sup> Gábor Blaskó<sup>b</sup> and László Tőke<sup>a</sup>

<sup>a</sup>Research Group of the Hungarian Academy of Sciences, Department of Organic Chemical Technology, Technical University of Budapest, H-1521 Budapest PO Box 91, Hungary

<sup>b</sup>EGIS Pharmaceuticals Ltd, H-1475 Budapest PO Box 100, Hungary

Received 27 April 2005; revised 24 May 2005; accepted 9 June 2005

Available online 5 July 2005

**Abstract**—A new route to the pyrrolo[3,4-*c*]quinoline ring system has been developed via the 1,5-dipolar electrocycloisatation reactions of azomethine ylides derived from easily available 3-formylquinoline derivatives. The intermediacy of azomethine ylides was shown by the trapping of the proposed dipoles with *N*-phenylmaleimide.

© 2005 Elsevier Ltd. All rights reserved.

## 1. Introduction

Quinolines and their derivatives are very important in medicinal chemistry because of their wide occurrence in natural products<sup>1</sup> and drugs.<sup>2</sup> Among the quinolines 2-chloro-3-formyl-quinolines occupy a prominent position as they are key intermediates for further [*b*]-annulation of a wide variety of rings and for various functional group interconversions.<sup>3</sup> The applications of these methodologies have yielded beside the huge number of new quinoline derivatives new synthetic approaches for alkaloids such as camptothecin,<sup>4</sup> luotonin A,<sup>5</sup> 22-hydroxyacuminatine<sup>6</sup> or nothapodytine<sup>7</sup> (Fig. 1).

In this paper, we describe<sup>8</sup> the first [*c*]-annulation of this type of quinoline by 1,5-electrocyclisation of azomethine ylides.<sup>9</sup> This conversion gives a direct route to the otherwise hardly accessible pyrrolo[3,4-*c*]quinoline ring system.<sup>10</sup>




Figure 1.


**Keywords:** Azomethine ylide; Cycloaddition; Electrocyclisation; Pyrroles.  
\* Corresponding author. Tel.: +36 14632213; fax: +36 14633648;  
e-mail: mnyerges@mail.bme.hu

The starting quinolines (**1a–c**) were prepared by the method described by Meth-Cohn from the corresponding acetanilides by the treatment with the Vilsmeier reagent in a single step.<sup>11</sup> The non-stabilized azomethine ylides **2** were generated from these aldehydes **1a–c** using the decarboxylation method.<sup>12</sup> The reaction of 2-chloro-3-formylquinolines **1a–c** with sarcosine in refluxing xylene gave 2-methyl-2,4,5,9*b*-tetrahydro-1*H*-pyrrolo[3,4-*c*]quinolin-4-ones **4a–c** in acceptable yields via the expected 1,5-electrocyclisation reaction accompanied by hydrolysis of the chlorine function under the applied reaction conditions in the presence of the water formed in the first step (Scheme 1).

The intermediacy of azomethine ylides **2** was shown by trapping the proposed dipoles with *N*-phenylmaleimide to give the two isomeric cycloadducts **5** and **6** (*endo–exo* ratio ≈ 1:1) in quantitative yield (Scheme 1).

After the successful 1,5-electrocyclisation of non-stabilised azomethine ylides, we studied the reactivity of the analogous ester-stabilised system generated from the corresponding Schiff-base **7** by thermal 1,2-prototropy.<sup>13</sup> In contrast, in these cases, no 1,5-electrocyclisation was observed, the **7** imine remained unchanged even after a prolonged reaction time in refluxing xylene (Scheme 2). This result is in good agreement with our earlier observations on the reactivity of azomethine ylides in electrocycloisatation reactions.<sup>14</sup>

We performed the next series of experiments with conjugated azomethine ylides derived from 2-phenyl-3-formylquinolines **10a–c**. In these dipoles **11** there is a



**Scheme 1.** (i) Sarcosine (2 equiv), xylene, 140 °C; (ii) *N*-phenylmaleimide (1 equiv).


possibility—besides the 1,5-electrocyclisation of a 1,7-electrocyclic ring closure onto the phenyl group.<sup>15</sup> The starting material was prepared in three simple steps from the 2-chloro-3-formyl-quinolines including a palladium catalysed Suzuki coupling with phenylboronic acid (Scheme 2).

The reaction of the resultant quinolines **10a–c** with sarcosine in refluxing xylene, gave 2-methyl-4-phenyl-1*H*-pyrrolo[3,4-*c*]quinolines **14a–c** as products in moderate yields (Scheme 3). The 1,5-electrocyclisations in these cases were followed by full aromatisation to the tetrahydro-1*H* pyrrolo[3,4-*c*]quinoline **13** ring system. This slightly different result compared to the transformation **1** ⇒ **4**, may


be explained by the delocalisation energy difference between the lactam products **4** and compounds **14** having a more extended conjugation.

The intermediacy of azomethine ylides **11** was again shown by the trapping the dipole with *N*-phenylmaleimide to give the two isomeric cycloadducts **15** and **16** (ratio ≈ 1:5) in good yield. The stereochemistry of the major isomer (**16**) was proved by NOE experiments (Scheme 4).


In conclusion, we have developed a new, one-step route from simple starting materials to the challenging pyrrolo[3,4-*c*]quinoline ring system via the 1,5-dipolar electrocyclic reaction of non-stabilised azomethine ylides.



**Scheme 2.** (i) EtO<sub>2</sub>CCH<sub>2</sub>NH<sub>2</sub>·HCl, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, rt; (ii) HOCH<sub>2</sub>CH<sub>2</sub>OH, PTSA, benzene, reflux; (iii) PhB(OH)<sub>2</sub>, Pd(OAc)<sub>2</sub> (cat.), K<sub>2</sub>CO<sub>3</sub>, DME, H<sub>2</sub>O; (iv) 5% HCl, THF, 80 °C.



**Scheme 3.** (i) Sarcosine (2 equiv), xylene, 140 °C.



**Scheme 4.** (i) *N*-Phenylmaleimide (1 equiv), sarcosine (2 equiv), xylene, 140 °C.

## 2. Experimental

Melting points were determined on a Gallenkamp apparatus and are uncorrected. Column chromatography was performed using Merck Kieselgel 60 70–230 mesh, TLC on aluminium sheets coated with Kieselgel 60 F<sub>254</sub>. Plates were stained with anisaldehyde solution (100 ml glacial acetic acid, 2 ml cc sulphuric acid and 1 ml anisaldehyde) and heated at ca. 150 °C. IR spectra were measured on a NICOLET FT-IR instrument. NMR spectra were obtained on a Bruker 250 instrument. Chemical shifts are given relative to  $\delta_{\text{TMS}}$ . All solvents were purified according to standard procedures and the quinolines **1a–c** were prepared by the method of Meth-Cohn et al.<sup>11</sup>

### 2.1. The 1,5-electrocyclisation reaction of azomethine ylides **2**. General procedure

The corresponding 2-chloro-quinoline-3-carbaldehyde **1a–c** (5.0 mmol), was dissolved in xylene (150 ml) and sarcosine (1.34 g; 15.0 mmol) was added. The reaction mixture was boiled for 4 h. After the reaction was completed all the solvents were removed in vacuo and the residue was purified by column chromatography (eluent: chloroform–methanol 8:1 vol/vol).

#### 2.1.1. 2-Methyl-2,4,5,9b-tetrahydro-1H-pyrrolo[3,4-c]

**quinolin-4-one (4a)**. Pale yellow powder (0.45 g, 45%); mp 145–6 °C; [Found: C, 72.0; H, 5.9; N, 14.0. C<sub>12</sub>H<sub>12</sub>N<sub>2</sub>O requires C 71.98; H 6.04; N 13.99%]; <sup>1</sup>H NMR (250 MHz, DMSO-*d*<sub>6</sub>): 7.79 (s, 1H, H-3), 7.66 (d, 1H, *J*=8.0 Hz, H-9), 7.54 (d, 1H, *J*=8.0 Hz, H-6), 7.44 (t, 1H, *J*=8.0 Hz, H-8), 7.14 (t, 1H, *J*=8.0 Hz, H-7), 5.77 (broad s, 1H, NH), 5.17 (broad s, 1H, H-9b), 3.69 (t, 1H, *J*=9.0 Hz, H-1), 3.30 (dd, 1H, *J*=2.2, 9.0 Hz, H-1), 2.99 (s, 3H, NCH<sub>3</sub>); <sup>13</sup>C NMR (62.5 MHz, DMSO-*d*<sub>6</sub>): 160.4 (q), 148.5 (q), 130.8 (CH), 128.9 (q), 128.8 (CH), 128.0 (CH), 125.4 (CH), 123.6 (q), 121.3 (CH), 66.0 (CH), 59.8 (CH<sub>2</sub>), 31.2 (CH<sub>3</sub>); IR (KBr, cm<sup>-1</sup>): 2944, 2868, 2790, 1651, 1581, 1541, 1507, 1446, 1408, 1359, 1308, 1286, 1252, 1150, 1106, 1071, 1038, 1002.

**2.1.2. 2-Methyl-8-methoxy-2,4,5,9b-tetrahydro-1H-pyrrolo[3,4-c]quinolin-4-one (4b)**. Pale yellow powder (0.56 g, 53%); mp 157–8 °C; [Found: C, 67.6; H, 6.0; N, 12.1. C<sub>13</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub> requires C 67.81; H 6.13; N 12.17%]; <sup>1</sup>H NMR (250 MHz, DMSO-*d*<sub>6</sub>): 7.75 (s, 1H, H-3), 7.48 (d, 1H, *J*=8.8 Hz, H-6), 7.17 (d, 1H, *J*=2.4 Hz, H-9), 7.11 (dd, 1H, *J*=2.4, 8.8 Hz, H-7), 5.74 (broad s, 1H, NH), 5.16 (broad s, 1H, H-9b), 3.79 (s, 3H, OCH<sub>3</sub>), 3.65 (dd, 1H, *J*=7.8, 10.5 Hz, H-1), 3.25 (dd, 1H, *J*=4.0, 10.5 Hz, H-1), 2.95 (s, 3H, NCH<sub>3</sub>); <sup>13</sup>C NMR (62.5 MHz, DMSO-*d*<sub>6</sub>): 159.5 (q), 154.0 (q), 143.5 (q), 130.2 (CH), 129.1 (q), 126.5 (CH), 124.0 (q), 119.2 (CH), 108.1 (CH), 66.2 (CH), 60.0 (CH<sub>2</sub>),

55.3 (CH<sub>3</sub>), 34.4 (CH<sub>3</sub>); IR (KBr, cm<sup>-1</sup>): 3160, 3062, 2994, 2939, 2831, 1648, 1618, 1582, 1500, 1453, 1430, 1404, 1336, 1292, 1235, 1204, 1166, 1097, 1062, 1038.

**2.1.3. 2,6-Dimethyl-2,4,5,9b-tetrahydro-1H-pyrrolo[3,4-c]quinolin-4-one (4c).** Pale yellow powder (0.55 g, 52%); mp 151 °C; [Found: C, 72.9; H, 6.4; N, 13.0. C<sub>13</sub>H<sub>14</sub>N<sub>2</sub>O requires C 72.87; H 6.59; N 13.07%]; <sup>1</sup>H NMR (250 MHz, DMSO-*d*<sub>6</sub>): 7.77 (s, 1H, H-3), 7.49 (d, 1H, *J*=7.5 Hz, H-9), 7.32 (d, 1H, *J*=7.5 Hz, H-7), 7.04 (t, 1H, *J*=7.5 Hz, H-8), 5.80 (broad s, 1H, NH), 5.09 (broad s, 1H, H-9b), 3.66 (dd, 1H, *J*=7.7, 10.2 Hz, H-1), 3.29 (dd, 1H, *J*=3.9, 10.2 Hz, H-1), 3.01 (s, 3H, NCH<sub>3</sub>), 2.56 (s, 3H, CH<sub>3</sub>); <sup>13</sup>C NMR (62.5 MHz, DMSO-*d*<sub>6</sub>): 159.7 (q), 147.1 (q), 132.5 (q), 131.1 (CH), 129.1 (CH), 128.3 (q), 126.0 (CH), 123.1 (q), 120.8 (CH), 66.1 (CH), 59.8 (CH<sub>2</sub>), 31.1 (CH<sub>3</sub>), 17.8 (CH<sub>3</sub>); IR (KBr, cm<sup>-1</sup>): 2942, 2860, 1653, 1583, 1543, 1511, 1442, 1361, 1318, 1256, 1151, 1111, 1071, 1032, 1012.

## 2.2. The 1,3-dipolar cycloaddition of azomethine ylides 2 to *N*-phenyl-maleimide. General procedure

The corresponding 2-chloro-quinoline-3-carbaldehyde **1a-c** (1.0 mmol), was dissolved in xylene (50 ml) and *N*-phenyl-maleimide (0.17 g; 1 mmol), sarcosine (0.36 g; 4.0 mmol) was added. The reaction mixture was boiled for 2 h. After the reaction was completed all the solvents were removed in vacuo and the residue was purified by column chromatography (eluent: hexanes–acetone 3:1 vol/vol).

**2.2.1. 5-(2-Chloroquinolin-3-yl)-1,4-diaza-2,6-dioxo-4-methyl-1-phenyl-bicyclo[3.3.0]octane (5a and 6a).** White powder (0.35 g, 95%); 1:1 mixture of two diastereomers; <sup>1</sup>H NMR (250 MHz, CDCl<sub>3</sub>): 8.27 (s, ½H, Ar-4'H), 8.16 (s, ½H, Ar-4'H), 8.03 (d, ½H, *J*=8.2 Hz, Ar-5'H), 7.83 (d, ½H, *J*=8.2 Hz, Ar-5'H), 7.77–7.27 (m, 8H, Ar-6', 7' and 8'H, Ph-H), 4.37 (d, ½H, *J*=6.0 Hz, H-5), 4.09 (d, ½H, *J*=8.5 Hz, H-5), 3.90 (t, ½H, *J*=8.5 Hz, H-5a), 3.79–3.55 (m, 3½H, H-2a, H-5a, H-3), 2.29 (s, 1½H, NCH<sub>3</sub>), 2.23 (s, 1½H, NCH<sub>3</sub>); IR (KBr, cm<sup>-1</sup>): 3060, 2972, 2940, 2836, 2780, 1708, 1619, 1591, 1560, 1496, 1456, 1388, 1320, 1188, 1172, 1158, 1043, 1010; HRMS: Calcd: 373.1426 for C<sub>22</sub>H<sub>19</sub>N<sub>3</sub>O<sub>3</sub>; Found: 373.1434.

**2.2.2. 5-(2-Chloro-6-methoxyquinolin-3-yl)-1,4-diaza-2,6-dioxo-4-methyl-1-phenyl-bicyclo[3.3.0]octane (5b and 6b).** White powder (0.40 g, 99%); 1:1 mixture of two diastereomers; <sup>1</sup>H NMR (250 MHz, CDCl<sub>3</sub>): 8.17 (s, ½H, Ar-4'H), 8.08 (s, ½H, Ar-4'H), 7.93 (d, ½H, *J*=8.2 Hz, Ar-8'H), 7.90 (d, ½H, *J*=8.2 Hz, Ar-8'H), 7.51–7.26 (m, 5H, Ar-6' and 7'H, Ph-H), 7.17–6.95 (m, 3H, Ar-5'H and Ph-H), 4.35 (d, ½H, *J*=6.0 Hz, H-5), 4.08 (d, ½H, *J*=8.5 Hz, H-5), 3.93 (s, 1½H, OCH<sub>3</sub>), 3.91 (s, 1½H, OCH<sub>3</sub>), 3.87–3.41 (m, 4H, H-2a, H-5a, H-3), 2.24 (s, 3H, NCH<sub>3</sub>); IR (KBr, cm<sup>-1</sup>): 2964, 2794, 1714, 1621, 1589, 1498, 1453, 1498, 1385, 1326, 1262, 1231, 1183, 1096, 1025; HRMS: Calcd: 403.1532 for C<sub>23</sub>H<sub>21</sub>N<sub>3</sub>O<sub>4</sub>; Found: 403.1534.

**2.2.3. 5-(2-Chloro-8-methylquinolin-3-yl)-1,4-diaza-2,6-dioxo-4-methyl-1-phenyl-bicyclo[3.3.0]octane (5c and 6c).** White powder (0.37 g, 95% 1:1 mixture of two

diastereomers); <sup>1</sup>H NMR (250 MHz, CDCl<sub>3</sub>): 8.21 (s, ½H, Ar-4'H), 8.11 (s, ½H, Ar-4'H), 7.55–7.25 (m, 8H, Ar-5', 6' and 7'H, Ph-H), 4.39 (d, ½H, *J*=6.0 Hz, H-5), 4.09 (d, ½H, *J*=8.5 Hz, H-5); 3.89 (t, ½H, *J*=8.5 Hz, H-5a), 3.78–3.39 (m, 3½H, H-2a, H-5a, H-3), 2.77 (s, 1½H, CH<sub>3</sub>), 2.75 (s, 1½H, CH<sub>3</sub>), 2.28 (s, 1½H, NCH<sub>3</sub>), 2.22 (s, 1½H, NCH<sub>3</sub>); IR (KBr, cm<sup>-1</sup>): 2944, 2846, 1708, 1596, 1497, 1483, 1389, 1323, 1185, 1140, 1089, 1027, 941; HRMS: Calcd: 387.1582 for C<sub>23</sub>H<sub>21</sub>N<sub>3</sub>O<sub>3</sub>; Found: 387.1588.

**2.2.4. Ethyl-(2-chloroquinolin-3-yl)methyleneaminoacetate (7).** The 2-chloroquinoline-3-carbaldehyde **1a** (0.38 g; 2.0 mmol) was dissolved in dry dichloromethane (40 ml). Ethyl glycinate hydrochloride (0.28 g; 2.0 mmol), and triethylamine (0.29 ml, 0.2 g; 2.0 mmol) and approximately 2 g anhydrous magnesium sulfate was added. The reaction mixture was stirred at room temperature overnight. After filtration the reaction mixture was evaporated in vacuo. The resulted solid was suspended in ether and filtered again. The ethereal solution was evaporated in vacuo to yield the title product as a pale yellow solid (0.52 g, 94.0%); mp 121–2 °C; <sup>1</sup>H NMR (250 MHz, CDCl<sub>3</sub>): 8.88 (s, 1H, CH=N), 8.78 (s, 1H, H-4), 7.99 (d, 1H, *J*=8.3 Hz, H-5), 7.87 (d, 1H, *J*=8.3 Hz, H-6), 7.76 (t, 1H, *J*=8.3 Hz, H-8), 7.56 (t, 1H, *J*=8.3 Hz, H-7), 4.53 (s, 2H, NCH<sub>2</sub>), 4.29 (q, 2H, *J*=7.8 Hz, OCH<sub>2</sub>), 1.33 (t, 2H, *J*=7.8 Hz, CH<sub>3</sub>); <sup>13</sup>C NMR (62.5 MHz, CDCl<sub>3</sub>): 169.6 (q), 161.1 (CH), 148.4 (q), 137.8 (CH), 131.7 (CH), 130.7 (q), 128.7 (CH), 128.2 (CH), 127.5 (CH), 126.9 (q), 126.6 (q), 62.0 (CH<sub>2</sub>), 61.2 (CH<sub>2</sub>), 14.1 (CH<sub>3</sub>); IR (KBr, cm<sup>-1</sup>): 2981, 2877, 1743, 1646, 1596, 1488, 1373, 1268, 1187, 1087, 1029; HRMS: Calcd: 276.0665 for C<sub>14</sub>H<sub>13</sub>N<sub>2</sub>O<sub>2</sub>Cl; Found: 276.0660.

## 2.3. Synthesis of 3-[1,3-dioxolane-2-yl]-2-chloroquinolines (8a–c). General procedure

The corresponding 2-chloroquinoline-3-carbaldehyde **1a-c** (60 mmol) was suspended in benzene (600 ml), and ethylene glycol (4.5 ml, 5.0 g; 80.0 mmol) and *p*-toluenesulphonic acid (0.57 g; 3.0 mmol) was added. The reaction mixture was refluxed for 4 h with the continuous removal of the formed water by the aid of a Dean–Stark trap. After the reaction was completed saturated aq sodium hydrogen carbonate solution (150 ml) was added. The organic layer was separated, and washed with water (2×100 ml) and brine (100 ml), dried over magnesium sulfate, and evaporated under reduced pressure to give the title products.

**2.3.1. 3-(1,3-Dioxolane-2-yl)-2-chloroquinoline (8a).** Pale yellow solid (14.12 g, 100%); mp 59–60 °C; <sup>1</sup>H NMR (250 MHz, CDCl<sub>3</sub>): 8.58 (s, 1H, H-4), 8.26 (d, 1H, *J*=8.0 Hz, H-5), 7.58–7.41 (m, 2H, H-8 and H-6), 7.17 (t, 1H, *J*=8.0 Hz, H-7), 6.08 (s, 2H, CH), 4.13–4.06 (m, 4H, OCH<sub>2</sub>CH<sub>2</sub>O); <sup>13</sup>C NMR (62.5 MHz, CDCl<sub>3</sub>): 148.5 (q), 137.3 (CH), 131.4 (CH), 130.9 (q), 128.8 (CH), 128.0 (CH), 127.1 (CH), 126.5 (q), 126.2 (q), 100.2 (CH), 65.3 (2×CH<sub>2</sub>); IR (KBr, cm<sup>-1</sup>): 2894, 1619, 1599, 1568, 1493, 1456, 1368, 1327, 1138, 1101, 1037; HRMS: Calcd: 235.0400 for C<sub>12</sub>H<sub>10</sub>NO<sub>2</sub>Cl; Found: 235.0402.

**2.3.2. 3-(1,3-Dioxolane-2-yl)-2-chloro-6-methoxy-quinoline (8b).** Pale yellow solid (15.74 g, 98%); mp 79–80 °C; <sup>1</sup>H NMR (250 MHz, DMSO-*d*<sub>6</sub>): 8.20 (s, 1H, H-4), 7.81 (d,

1H,  $J=9.2$  Hz, H-8), 7.28 (dd, 1H,  $J=2.8, 9.2$  Hz, H-7), 6.97 (d, 1H,  $J=2.8$  Hz, H-5), 6.12 (s, 1H, CH), 4.11–4.08 (m, 2H,  $OCH_2$ ), 4.05–4.00 (m, 2H,  $OCH_2$ ), 3.81 (s, 3H,  $OCH_3$ );  $^{13}C$  NMR (62.5 MHz, DMSO- $d_6$ ): 159.5 (q), 145.8 (q), 142.7 (q), 135.7 (CH), 129.0 (q), 128.9 (CH), 128.0 (q), 123.5 (CH), 106.3 (CH), 99.7 (CH), 65.0 ( $2\times CH_2$ ), 55.5 (CH $_3$ ); IR (KBr,  $cm^{-1}$ ): 3015, 2960, 2903, 1622, 1596, 1498, 1333, 1225, 1179, 1107, 1043, 1022. HRMS: Calcd: 265.0505 for  $C_{13}H_{12}NO_3Cl$ ; Found: 265.0501.

**2.3.3. 3-(1,3-Dioxolane-2-yl)-2-chloro-8-methyl-quinoline (8c).** Pale yellow solid (14.80 g, 99%); mp 71–2 °C;  $^1H$  NMR (250 MHz,  $CDCl_3$ ): 8.31 (s, 1H, H-4), 7.61 (d, 1H,  $J=8.0$  Hz, H-5), 7.51 (d, 1H,  $J=8.0$  Hz, H-7), 7.38 (t, 1H,  $J=8.2$  Hz, H-6), 6.20 (s, 1H, CH), 4.09 (m, 4H,  $OCH_2CH_2O$ ), 2.72 (s, 3H,  $CH_3$ );  $^{13}C$  NMR (62.5 MHz,  $CDCl_3$ ): 146.9 (q), 136.8 (CH), 136.4 (q), 131.0 (CH), 129.1 (q), 128.5 (q), 127.7 (q), 126.8 (CH), 125.9 (CH), 100.5 (CH), 65.5 ( $2\times CH_2$ ), 17.8 ( $CH_3$ ); IR (KBr,  $cm^{-1}$ ): 2954, 2884, 1615, 1598, 1577, 1490, 1466, 1364, 1331, 1182, 1101, 1074, 1021; HRMS: Calcd: 249.0556 for  $C_{13}H_{12}NO_2Cl$ ; Found: 249.0549.

## 2.4. Suzuki coupling. General procedure

The corresponding acetal (20 mmol) and phenylboronic acid (2.93 g; 24.0 mmol) was dissolved in DME (75 ml) under argon atmosphere. Potassium carbonate (8.3 g; 60 mmol) dissolved in water (75 ml) was added followed by palladium(II) acetate (49 mg; 0.2 mmol) and triphenyl phosphine (0.21 g; 0.8 mmol). The reaction mixture was refluxed for 1 h. After the reaction was completed it was filtered through a pad of Celite and washed with ethyl acetate. The organic layer was separated and the aqueous phases was extracted with ethyl acetate ( $2\times 50$  ml). The combined organic extracts were washed with saturated aq sodium hydrogen carbonate solution (50 ml), water ( $2\times 50$  ml) and brine (50 ml), dried over magnesium sulfate, and evaporated under reduced pressure to give the crude product, which was purified by flash vacuum chromatography (eluent: hexanes–ethyl acetate 3:1 vol/vol).

**2.4.1. 3-(1,3-Dioxolane-2-yl)-2-phenylquinoline (9a).** White powder (5.50 g, 99%); mp 88–90 °C;  $^1H$  NMR (250 MHz,  $CDCl_3$ ): 8.58 (s, 1H, H-4), 8.21 (d, 1H,  $J=8.1$  Hz, H-5), 7.87 (d, 1H,  $J=8.1$  Hz, H-8), 7.81–7.72 (m, 3H, H-6 and Ph-H), 7.54–7.41 (m, 4H, H-7 and Ph-H), 5.88 (s, 1H, CH), 4.18–4.07 (m, 2H,  $OCH_2$ ), 4.00–3.90 (m, 2H,  $OCH_2$ );  $^{13}C$  NMR (62.5 MHz,  $CDCl_3$ ): 158.8 (q), 147.7 (q), 139.1 (q), 135.5 (CH), 130.2 (CH), 129.5 ( $2\times CH$ ), 129.0 (CH), 128.4 (q), 128.3 (CH), 127.9 ( $2\times CH$ ), 127.7 (CH), 126.7 (q), 126.4 (CH), 100.7 (CH), 65.3 ( $2\times CH_2$ ); IR (KBr,  $cm^{-1}$ ): 3058, 2953, 2889, 1621, 1599, 1558, 1489, 1442, 1368, 1267, 1169, 1128, 1082, 1018; HRMS: Calcd: 277.1102 for  $C_{18}H_{15}NO_2$ ; Found: 277.1100.

**2.4.2. 3-(1,3-Dioxolane-2-yl)-6-methoxy-2-phenylquinoline (9b).** White powder (5.60 g, 91%); mp 102–3 °C;  $^1H$  NMR (250 MHz,  $CDCl_3$ ): 8.42 (s, 1H, H-4), 8.04 (d, 1H,  $J=7.6$  Hz, H-8), 7.75 (d, 2H,  $J=7.5$  Hz, Ph-2' and 6'H), 7.41–7.28 (m, H-7 and Ph-H), 7.01 (s, 1H, H-5), 5.81 (s, 1H, CH), 4.02 (m, 2H,  $OCH_2$ ), 3.82 (m, 2H,  $OCH_2$ ), 3.70 (s, 3H,  $OCH_3$ );  $^{13}C$  NMR (62.5 MHz,  $CDCl_3$ ): 157.7 (q), 156.5 (q),

144.0 (q), 139.4 (q), 134.3 (CH), 130.4 (CH), 129.6 ( $2\times CH$ ), 129.3 (q), 128.3 (CH), 128.0 ( $2\times CH$ ), 123.3 (CH), 115.5 (q), 104.9 (CH), 100.8 (CH), 65.4 ( $2\times CH_2$ ), 55.3 ( $OCH_3$ ); IR (KBr,  $cm^{-1}$ ): 3056, 2999, 2964, 2888, 2861, 1622, 1602, 1492, 1462, 1364, 1223, 1168, 1085, 1029; HRMS: Calcd: 307.1208 for  $C_{19}H_{17}NO_3$ ; Found: 307.1212.

**2.4.3. 3-(1,3-Dioxolane-2-yl)-8-methyl-2-phenylquinoline (9c).** White powder (5.79 g, 99%); mp 98–9 °C;  $^1H$  NMR (250 MHz,  $CDCl_3$ ): 8.51 (s, 1H, H-4), 7.84 (d, 2H,  $J=7.8$  Hz, Ph-2' and 6'H), 7.69 (d, 1H,  $J=8.1$  Hz, H-9), 7.53–7.35 (m, 6H, H-8, H-7 and Ph-H), 5.90 (s, 1H, CH), 4.16 (m, 2H,  $OCH_2$ ), 3.95 (m, 2H,  $OCH_2$ ), 2.81 (s, 3H,  $CH_3$ );  $^{13}C$  NMR (62.5 MHz,  $CDCl_3$ ): 157.3 (q), 147.0 (q), 139.8 (q), 137.3 (q), 135.7 (CH), 130.1 (CH), 130.0 ( $2\times CH$ ), 128.3 (q), 128.2 (CH), 127.9 ( $2\times CH$ ), 126.7 (q), 126.2 (CH), 125.8 (CH), 101.0 (CH), 65.5 ( $2\times CH_2$ ), 17.8 ( $CH_3$ ); IR (KBr,  $cm^{-1}$ ): 2953, 2892, 1615, 1599, 1568, 1481, 1463, 1365, 1170, 1084, 1072, 1062, 1009; HRMS: Calcd: 291.1259 for  $C_{19}H_{17}NO_2$ ; Found: 291.1265.

## 2.5. Hydrolysis of ketal 9a–c—General procedure

The corresponding ketal 9a–c (20 mmol) was dissolved in tetrahydrofuran (300 ml), water (50 ml) and concentrated hydrochloric acid (10 ml) was added. The reaction mixture was refluxed for an hour under argon atmosphere. After the reaction was completed saturated aq sodium hydrocarbonate solution (150 ml) was added. The tetrahydrofurane was removed in vacuo and the residue was extracted with ethyl acetate ( $3\times 50$  ml). The combined organic extracts were washed with water ( $2\times 50$  ml), brine (50 ml), dried over magnesium sulfate, and evaporated under reduced pressure to give the product.

**2.5.1. 2-Phenyl-quinoline-3-carbaldehyde (10a).** White powder (3.50 g, 100%); mp 105–6 °C; [Found: C, 82.5; H, 4.8; N, 6.0.  $C_{16}H_{11}NO$  requires C 82.38; H 4.75; N 6.00%];  $^1H$  NMR (250 MHz,  $CDCl_3$ ): 10.15 (s, 1H, CHO), 8.79 (s, 1H, H-4), 8.19 (d, 1H,  $J=8.2$  Hz, H-8), 7.96 (d, 1H,  $J=8.2$  Hz, H-5); 7.83 (t, 1H,  $J=8.2$  Hz, H-7), 7.68 (m, 2H, Ph-H), 7.52 (m, 4H, H-6 and Ph-H);  $^{13}C$  NMR (62.5 MHz,  $CDCl_3$ ): 191.3 (CH), 160.1 (q), 149.4 (q), 138.0 (CH), 137.5 (q), 132.5 (CH), 130.1 ( $2\times CH$ ), 129.4 (CH), 129.3 (CH), 129.25 (CH), 128.6 ( $2\times CH$ ), 127.5 (q), 127.3 (CH), 126.2 (q); IR (KBr,  $cm^{-1}$ ): 2861, 1693, 1614, 1584, 1552, 1485, 1370, 1156, 1121, 1075, 1008.

**2.5.2. 6-Methoxy-2-phenylquinoline-3-carbaldehyde (10b).** White powder (3.82 g, 97%); mp 125–6 °C; [Found: C, 77.3; H, 4.8; N, 5.2.  $C_{17}H_{13}NO_2$  requires C 77.55; H 4.98; N 5.32%];  $^1H$  NMR (250 MHz,  $CDCl_3$ ): 10.14 (s, 1H, CHO), 8.66 (s, 1H, H-4), 8.15 (d, 1H,  $J=8.3$  Hz, H-8), 7.64 (m, 2H, Ph-H), 7.51 (m, 4H, H-7 and Ph-H), 7.16 (d, 1H,  $J=1.8$  Hz, H-5), 3.93 (s, 3H,  $OCH_3$ );  $^{13}C$  NMR (62.5 MHz,  $CDCl_3$ ): 191.7 (CH), 158.3 (q), 158.0 (q), 145.9 (q), 137.8 (q), 136.4 (CH), 130.9 (CH), 130.3 ( $2\times CH$ ), 129.4 (CH), 128.7 ( $2\times CH$ ), 127.7 (q), 127.4 (q), 125.8 (CH), 125.9 (CH), 55.6 ( $OCH_3$ ); IR (KBr,  $cm^{-1}$ ): 3452, 3057, 2955, 2855, 1686, 1618, 1585, 1563, 1492, 1446, 1416, 1367, 1349, 1226, 1169, 1130, 1027.

**2.5.3. 8-Methyl-2-phenylquinoline-3-carbaldehyde (10c).**

White powder (3.48 g, 94%); mp 109–11 °C; [Found: C, 82.7; H, 5.4; N, 5.7. C<sub>17</sub>H<sub>13</sub>NO requires C 82.57; H 5.30; N 5.66%]; <sup>1</sup>H NMR (250 MHz, CDCl<sub>3</sub>): 10.16 (s, 1H, CHO), 8.71 (s, 1H, H-4), 7.76–7.40 (m, 8H, Ar-H), 2.81 (s, 3H, CH<sub>3</sub>); <sup>13</sup>C NMR (62.5 MHz, CDCl<sub>3</sub>): 191.7 (CH), 158.5 (q), 148.5 (q), 138.2 (CH), 137.7 (q), 132.4 (CH), 132.3 (q), 130.6 (2×CH), 129.2 (CH), 128.5 (2×CH), 128.4 (q), 127.2 (CH), 127.1 (CH), 126.1 (q), 17.8 (CH<sub>3</sub>); IR (KBr, cm<sup>-1</sup>): 2861, 2844, 1692, 1611, 1580, 1555, 1485, 1371, 1152, 1119, 1075, 1011.

## 2.6. 1,5-Electrocyclization reactions of azomethine ylides **11** generated from 2-phenyl-quinoline-3-carbaldehydes **10a–c**. General procedure

The corresponding 2-phenyl-quinoline-3-carbaldehyde **10a–c** (3.0 mmol) was dissolved in xylene (50 ml) and sarcosine (0.54 g; 6.0 mmol) was added. The reaction mixture was refluxed until the starting aldehyde completely disappeared (judged by TLC). All the solvent was removed in vacuo and the residue purified by flash chromatography (eluent: petroleum ether–acetone 3:1) to give the crystalline product.

### 2.6.1. 2-Methyl-4-phenyl-pyrrolo[3,4-*c*]quinoline (**14a**).

White powder (0.46 g, 59%); mp 182–3 °C; <sup>1</sup>H NMR (250 MHz, CDCl<sub>3</sub>): 8.10 (dd, 1H, *J* = 1.9, 7.9 Hz, H-9), 7.97 (dd, 2H, *J* = 2.0, 8.1 Hz, Ph-2' and 6'H), 7.92 (dd, 1H, *J* = 1.9, 7.9 Hz, H-6), 7.53–7.38 (m, 5H, H-7, H-8 and Ph-H), 7.27 (d, 1H, *J* = 1.8 Hz, H-3), 7.20 (d, 1H, *J* = 1.8 Hz, H-1), 3.77 (s, 3H, NCH<sub>3</sub>); <sup>13</sup>C NMR (62.5 MHz, CDCl<sub>3</sub>): 155.6 (q), 142.8 (q), 140.3 (q), 129.7 (CH), 129.0 (CH), 128.5 (2×CH), 128.4 (2×CH), 126.0 (CH), 125.8 (CH), 122.9 (q), 122.2 (CH), 121.9 (q), 117.6 (CH), 117.5 (q), 112.8 (CH), 37.4 (CH<sub>3</sub>); IR (KBr, cm<sup>-1</sup>): 3139, 2942, 1572, 1538, 1521, 1481, 1467, 1454, 1443, 1413, 1357, 1332, 1234, 1220, 1192, 1143, 1078, 1028; HRMS: Calcd: 258.1156 for C<sub>18</sub>H<sub>14</sub>N<sub>2</sub>; Found: 258.1156.

### 2.6.2. 8-Methoxy-2-methyl-4-phenyl-pyrrolo[3,4-*c*]quinoline (**14b**).

White powder (0.43 g, 50%); mp 188 °C; <sup>1</sup>H NMR (250 MHz, CDCl<sub>3</sub>): 8.01 (d, 1H, *J* = 9.0 Hz, H-6), 7.96 (m, 2H, Ar-H), 7.49 (m, 3H, Ar-H), 7.30 (m, 2H, Ar-H), 7.22 (d, 1H, *J* = 1.8 Hz, H-1), 7.09 (dd, 1H, *J* = 2.5, 9.0 Hz, H-7), 3.88 (s, 3H, OCH<sub>3</sub>), 3.83 (s, 3H, NCH<sub>3</sub>); <sup>13</sup>C NMR (62.5 MHz, CDCl<sub>3</sub>): 157.6 (q), 157.5 (q), 153.2 (q), 140.3 (q), 137.5 (q), 131.0 (CH), 128.8 (CH), 128.4 (2×CH), 128.3 (2×CH), 122.9 (q), 122.7 (q), 117.4 (CH), 114.9 (CH), 112.8 (CH), 103.8 (CH), 55.4 (OCH<sub>3</sub>), 37.4 (NCH<sub>3</sub>); IR (KBr, cm<sup>-1</sup>): 3142, 3058, 2933, 2832, 1706, 1616, 1531, 1485, 1474, 1452, 1434, 1369, 1250, 1210, 1165, 1141, 1104, 1030; HRMS: Calcd: 288.1262 for C<sub>19</sub>H<sub>16</sub>N<sub>2</sub>O; Found: 288.1263.

### 2.6.3. 2,6-Dimethyl-4-phenyl-pyrrolo[3,4-*c*]quinoline (**14c**).

White powder (0.39 g, 48%); mp 176–7 °C; <sup>1</sup>H NMR (250 MHz, CDCl<sub>3</sub>): 8.10 (d, 2H, *J* = 7.7 Hz, Ph-2' and 6'H), 7.81 (dd, 1H, *J* = 2.3, 6.7 Hz, H-9), 7.54–7.25 (m, 7H, Ar-H), 3.92 (s, 3H, NCH<sub>3</sub>), 2.82 (s, 3H, CH<sub>3</sub>); <sup>13</sup>C NMR (62.5 MHz, CDCl<sub>3</sub>): 152.4 (q), 140.2 (q), 139.8 (q), 136.4 (q), 128.2 (CH), 127.7 (2×CH), 127.6 (2×CH), 126.1 (CH), 124.6 (CH), 122.6 (q), 120.7 (q), 119.3 (CH), 116.5 (CH), 116.1 (q), 112.2 (CH), 36.7 (NCH<sub>3</sub>), 17.8 (CH<sub>3</sub>); IR

(KBr, cm<sup>-1</sup>): 3025, 2951, 1528, 1473, 1446, 1428, 1356, 1329, 1216, 1140, 1089, 1073, 1059, 1020; HRMS: Calcd: 272.1313 for C<sub>19</sub>H<sub>16</sub>N<sub>2</sub>; Found: 272.1313.

### 2.6.4. 5-(2-Phenyl-6-methoxy-quinolin-3-yl)-1,4-diaza-2,6-dioxo-4-methyl-1-phenyl-bicyclo[3.3.0]octane (**16**).

2-(6-Methoxyphenyl)-quinoline-3-carbaldehyde **10b** (0.26 g; 1 mmol) was dissolved in xylene (50 ml) and *N*-phenylmaleimide (0.17 g; 1.0 mmol) and sarcosine (0.36 g; 4.0 mmol) was added. The reaction mixture was refluxed for 1 h. On cooling the solvent was removed in vacuo and the residue was purified by flash chromatography (eluent: petroleum ether–acetone 3:1) to give the main isomer as a crystalline product as a white powder (0.30 g, 65%); mp 172–3 °C; <sup>1</sup>H NMR (250 MHz, DMSO-*d*<sub>6</sub>): 8.32 (s, 1H, Ar-4'H), 8.06 (d, 1H, *J* = 9 Hz, Ar-8'H), 7.52–7.37 (m, 9H, Ar-H, Ph-H), 7.10 (m, 3H, Ar-H, Ph-H), 3.93 (s, 3H, OCH<sub>3</sub>), 3.84 (d, 1H, *J* = 7.3 Hz, H-5), 3.65–3.50 (m, 4H, H-2a, H-3, H-5a), 2.07 (s, 3H, NMe); <sup>13</sup>C NMR (63 MHz, DMSO-*d*<sub>6</sub>): 176.2 (q), 175.5 (q), 158.4 (q), 157.9 (q), 143.4 (q), 139.9 (q), 134.7 (CH), 131.4 (q), 131.0 (q), 130.8 (CH), 129.8 (2×CH), 129.1 (2×CH), 128.6 (CH), 128.1 (2×CH), 127.9 (CH), 127.8 (q), 126.4 (2×CH), 123.1 (CH), 104.5 (CH), 68.0 (CH), 57.3 (CH<sub>2</sub>), 55.5 (CH<sub>3</sub>), 54.8 (CH), 44.2 (CH), 38.6 (CH<sub>3</sub>). HRMS: Calcd: 463.1895 for C<sub>29</sub>H<sub>25</sub>N<sub>3</sub>O<sub>3</sub>; Found: 463.1898.

## Acknowledgements

This work was financially supported by the National Found for Science and Research, Hungary (OTKA Project No. T 032221). M. N. thanks the Hungarian Academy of Sciences for a Bolyai J. fellowship. A grant from the József Varga Foundation provided to A. V. is gratefully appreciated.

## References and notes

- (a) Michael, J. P. *Nat. Prod. Rep.* **2004**, 650. (b) Michael, J. P. *Nat. Prod. Rep.* **2003**, 476.
- (a) Alhaider, A. A.; Abdelkader, M. A.; Lien, E. J. *J. Med. Chem.* **1985**, 28, 1398. (b) Campbell, S. F.; Hardstone, J. D.; Palmer, M. J. *J. Med. Chem.* **1988**, 31, 1031. (c) Wu, D. *Tetrahedron* **2003**, 59, 8649.
- Meth-Cohn, O. *Heterocycles* **1993**, 35, 539.
- (a) Rigby, J. H.; Danca, D. M. *Tetrahedron Lett.* **1997**, 38, 4969. (b) Leue, S.; Miao, W.; Kanazawa, A.; Génisson, Y.; Garçon, S.; Greene, A. E. *J. Chem. Soc., Perkin Trans. 1* **2001**, 2903. (c) Comins, D. L.; Nolan, J. M. *Org. Lett.* **2001**, 3, 1611.
- (a) Toyota, M.; Komori, C.; Ihara, M. *Heterocycles* **2002**, 56, 101. (b) Chavan, S. P.; Sivappa, R. *Tetrahedron Lett.* **2004**, 45, 3113. (c) Chavan, S. P.; Sivappa, R. *Tetrahedron* **2004**, 60, 9931. (d) Harayama, T.; Morikami, Y.; Shigeta, Y.; Abe, H.; Takeuchi, Y. *Synlett* **2003**, 847.
- Ma, Z.; Lee, D. Y. *Z. Tetrahedron Lett.* **2004**, 45, 6721.
- Carles, L.; Narkunan, K.; Penlou, S.; Rousset, L.; Bouchu, D.; Ciufolini, M. A. *J. Org. Chem.* **2002**, 67, 4304.
- This work has been published in preliminary form: Pintér, A.; Nyerges, M.; Virányi, A.; Töke, L. *Tetrahedron Lett.* **2003**, 44, 2343.

9. For excellent reviews on 1,5-dipolar cyclisations, see: (a) Taylor, E. C.; Turchi, I. J. *Chem. Rev.* **1979**, *79*, 181. (b) Huisgen, R. *Angew. Chem., Int. Ed. Engl.* **1980**, *19*, 947.
10. There have been only a few reports on the preparation pyrrolo[3,4-*c*]quinolines: (a) Horner, L. *Justus Liebigs Ann. Chem.* **1941**, *548*, 117. (b) Roy, R. B.; Swan, G. A. *J. Chem. Commun.* **1968**, 1446. (c) Roy, R. B.; Swan, G. A. *J. Chem. Soc. C* **1969**, 1886. (d) Murata, G.; Satoru, H.; Teramoto, K.; Miura, M.; Nomura, M. *Heterocycles* **1993**, *36*, 2147. (e) Swan, G. A.; Roy, R. B.; Khandelwal, G. D. *J. Chem. Soc.* **1974**, 891. (f) Jones, K.; Wilkinson, J. J. *J. Chem. Soc., Chem. Commun.* **1992**, 1767. (g) Veenstra, S. J.; Fortgens, R.; Vijn, R. J.; Jong, B. S.; Speckamp, W. N. *Tetrahedron* **1987**, *43*, 1147. (h) Gündel, W.-F.; Bohnert, S. Z. *Naturforschung* **1985**, *40b*, 1409. (i) Virányi, A.; Nyerges, M.; Blaskó, G.; Tőke, L. *Synthesis* **2003**, 2655.
11. (a) Meth-Cohn, O.; Narine, B. *Tetrahedron Lett.* **1978**, *19*, 2045. (b) Meth-Cohn, O.; Narine, B.; Tarnowski, B. *J. Chem. Soc., Perkin Trans. 1* **1981**, 1520.
12. (a) Tsuge, O.; Kanemasa, S.; Ohe, M.; Takenaka, S. *Bull. Chem. Soc. Jpn.* **1987**, *60*, 4079. (b) Nyerges, M.; Balázs, L.; Bitter, I.; Kádas, I.; Kövesdi, I.; Tőke, L. *Tetrahedron* **1995**, *51*, 6783. (c) Arany, A.; Groundwater, P. W.; Nyerges, M. *Tetrahedron Lett.* **1998**, *39*, 3267.
13. Tsuge, O.; Kanemasa, S. *Adv. Heterocycl. Chem.* **1989**, *45*, 232–349.
14. Nyerges, M.; Arany, A.; Fejes, I.; Groundwater, P. W.; Zhang, W.; Bendell, D.; Anderson, R. J.; Tőke, L. *Tetrahedron* **2002**, *58*, 989.
15. (a) Groundwater, P. W.; Nyerges, M. *Adv. Heterocycl. Chem.* **1999**, *73*, 97–129. (b) Arany, A.; Bendell, D.; Groundwater, P. W.; Garnett, I.; Nyerges, M. *J. Chem. Soc., Perkin Trans. 1* **1999**, 2605. (c) Nyerges, M.; Virányi, A.; Pintér, Á.; Tőke, L. *Tetrahedron Lett.* **2003**, *44*, 793. (d) Pintér, Á.; Nyerges, M.; Virányi, A.; Bitter, I.; Tőke, L. *Tetrahedron Lett.* **2005**, *46*, 377.